FIELD: oncology.
SUBSTANCE: method comprises administering to an animal, requiring this treatment, in a synergetic mode, therapeutically effective amount of (i) agent selected from group including cytotoxic agents and cytostatic agents and (ii) compound of formula I (given in description) or pharmaceutically acceptable salt thereof. Method provides synergic antitumor effect when using diminished doses of one or both active ingredients, prevents or slows development of multidrug resistance of tumor while ensuring destruction of both proliferative and non-proliferative tumor cells.
EFFECT: enabled use of reduced doses of drugs.
7 cl, 23 dwg, 6 tbl, 25 ex
Title | Year | Author | Number |
---|---|---|---|
COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR, COMPOSITION OF RAS-FARNESYLT RANSFERASE INHIBITOR, PHARMACEUTICAL COMPOSITION | 1999 |
|
RU2230062C2 |
SYNERGETIC PHARMACEUTICAL COMBINATION FOR CANCER TREATMENT | 2007 |
|
RU2438664C2 |
TYPES OF COMBINED THERAPY FOR CANCER TREATMENT | 2016 |
|
RU2727474C2 |
N,N'((ALKANDIYL)BIS[LABDA-7(9),13,14-TRIENE-4-CARBOXAMIDES] WITH ANTITUMOUR ACTIVITY | 2017 |
|
RU2654201C1 |
PHARMACEUTICAL COMBINATION FOR TREATMENT AND/OR CHEMOSENSITISATION OF TUMOURS RESISTANT TO ANTICANCER DRUGS | 2007 |
|
RU2396974C2 |
COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
METHOD OF PREVENTION AND/OR TREATMENT OF CANCEROUS DISEASES | 2006 |
|
RU2480201C2 |
Authors
Dates
2005-11-20—Published
2001-03-22—Filed